Ocuco has announced a minority investment in Ocumetra, a company that provides data science solutions for the eyecare industry. As a part of the equity deal, Leo Mac Canna, Ocuco’s CEO, joins Ocumetra’s board. In addition, Ocumetra’s machine learning tools will be integrated with Ocuco’s next-generation, cloud-hosted Practice Management Software (PMS).

Ocumetra’s product portfolio comprises nine clinical tools, including interactive ocular growth charts, myopia treatment efficacy analytics, risk indicators and other clinical decision support tools, such as the Refractogram. The Refractogram makes advanced myopia treatment accessible to all, providing evidence-based, detailed graphical and numerical indicators of treatment efficacy. It allows therapy decisions to be optimised and care benefits to be demonstrated to every patient.

“Ocuco sees myopia control as a key opportunity for the industry, and we see our role as providing tools to support ECPs deliver myopia control to their patients. Integrating Ocumetra’s clinical tools into our next-generation PMS brings the clinical support that ECPs need to support this new area within their practice management and EMR system, “explains Leo Mac Canna, Ocuco CEO.

Ocumetra was founded in 2020 by Professor James Loughman and Professor Ian Flitcroft. The data science company aims to deliver personalised myopia care solutions and vital decision support to practitioners in this rapidly changing field of clinical practice. According to James Loughman, Ocumetra’s clinical tools were built based on information from over one million eyes from all over the world. Consequently, its machine learning solutions are suitable for eyecare professionals worldwide.